Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Sponsor
Children's Hospital of Fudan University
Study ID
NCT04534270
Phase
PHASE4
Status
Completed

Conditions

  • Proteinuria

Eligibility Criteria

Sex
ALL
Age
6 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    Dapagliflozin will be given 5mg per day (weight≤30kg) or 10mg per day (weight\>30kg), for 12 weeks

Study Details

The purpose of the study is to investigate the antiproteinuric effect of Dapagliflozin in children with proteinuria.

Key Dates

Start date
Jul 6, 2020
Status verified
Feb 2022
Primary completion
Dec 30, 2021
Completion
Mar 30, 2022

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin treatment

Primary Outcome Measure

The change in 24-hr proteinuria after a 4 weeks treatment with dapagliflozin [ Time Frame: From baseline to weeks 4 ]

Related Studies